FDA clears IND for 4D-150 DME trial; places clinical hold on 4D-310 Fabry program after aHUS cases

4D Molecular Therapeutics, Inc.

FDA cleared IND for 4D-150 in diabetic macular edema; Phase 2 SPECTRA trial enrollment expected Q3 2023.
Initial 4D-150 wet AMD data showed >95% reduction in annualized anti-VEGF injections; Phase 2 PRISM enrolling.
4D-310 Fabry program placed on clinical hold by FDA after 3 atypical hemolytic uremic syndrome cases; no new enrollment.
Improvements in cardiac endpoints observed in 3 of 6 4D-310 patients at 12 months; FDA allows long-term follow-up.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.